丙型肝炎病毒高变区1抗体的交叉反应性分析

严艳; 修冰水; 殷继明; 张贺秋; 李卓

丙型肝炎病毒高变区1抗体的交叉反应性分析

1. 北京市肝病研究所
2. 军事医学科学院基础医学研究所

基金项目:

国家科技重大专项,传染病专项(2008ZX10002-013)；

详细信息

中图分类号: R446.6
计量
- 文章访问数: 3801
- HTML全文浏览量: 15
- PDF下载量: 627
- 被引次数: 0
出版历程
- 出版日期: 2011-08-20

Evaluation of cross-reactive antibody response to hypervariable region 1 of hepatitis C virus

Research funding:

摘要

摘要: 目的探索检测丙型肝炎病毒(HCV)高变区1(HVR1)抗体交叉反应性的意义。方法采用16种重组的HVR1抗原包被,酶联免疫吸附检测不同病程及不同干扰素治疗效果HCV感染者血清中HVR1抗体的情况,分析其高变区抗体交叉反应性。结果在慢性丙型肝炎、肝硬化和肝细胞癌这三组患者血清中HVR1抗体交叉反应阳性数目分别为10.93±4.98、12±5.57和10.64±4.83,三组间差异无统计学意义(P>0.05);对干扰素治疗效果好的患者HVR1抗体交叉反应阳性数为13.85±2.85,治疗效果差的患者为7±5.27,前者显著高于后者(P<0.05)。但两者治疗前HCV病毒载量差异无统计学意义(P>0.05)。结论 HVR1抗体的交叉反应性与HCV感染的严重程度无明显关系,但可能成为一项干扰素疗效的辅助预测指标。
- 肝炎病毒属 /
- 肝炎,丙型
Abstract: Objective To evaluate the significance of cross-reactive antibodies against hypervariable region 1 (HVR1) in hepatitis C virus (HCV) infected patients.Methods The cross-reactivity of HVR1 antibodies in the serum of HCV patients of different disease course and different response with interferon treatment were semiquantitatively done through counting the positive reaction with 16 representative HVR1 proteins coated on the micro-plates by ELISA.Results The cross-reactivity of HVR1 antibodies in the group of chronic hepatitis, cirrhosis and HCC was 10.93±4.979, 12±5.57, 10.64±4.83 respectively.There was no significant difference in the three groups (P>0.05) .The cross-reactivity of HVR1 antibodies was 13.85±2.85 in patients with sustained virological response (SVR) , which was significantly higher than that in the patients with no response to IFN (7±5.27) .There was no difference in the HCV RNA pretreatment level between the effective and ineffective groups (P>0.05) .Conclusion The cross-reactivity of anti-HVR1 antibody was not related to the progress of chronic HCV infection, which may be potential application in predicting the therapy outcome in chronic HCV patients.
- hepacivirus /
- hepatitis C

HTML全文

参考文献(11)

[1]Wasley A, Alter MJ.Epidemiology of hepatitis C:geographicdifferences and temporal trends[J].Semin Liver Dis, 2000, 20 (1) :1-16.

[2]Kiyosawa K, Sodeyama T, Tanaka E, et al.Interrelationship ofblood transfusion, non-A, non-B hepatitis and hepatocellularcarcinoma:analysis by detection of antibody to hepatitis C virus[J].Hepatology, 1990, 12 (4 Pt 1) :671-675.

[3]Tarr AW, Owsianka AM, Jayaraj D, et al.Determination of the hu-man antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33[J].J Gen Virol, 2007, 88 (Pt 11) :2991-300l.

[4]Qin H, Shire NJ, Keenan ED, et al.HCV quasispecies evolutionassociation with progression to end-stage liver disease in hemophil-iacs infected with HCV to HCV/HIV[J].Blood, 2005, 105 (2) :533-541.

[5]修冰水, 王国华, 张贺秋, 等.慢性肝炎病毒感染者体内第一高变区抗体的变化规律[J].军事医学科学院院刊, 2008, 32 (4) :332-334.

[6]Xiu BS, Ling SG, Song XG, et al.Cross-reactivity of hypervari-able region 1 chimera of hepatitis C virus[J].World J Gastroen-terol, 2003, 9 (6) :1256-1260.

[7]修冰水, 王国华, 张贺秋, 等.献血人群中丙型肝炎病毒第1高变区抗体检测及意义[J].中国输血杂志, 2008, 21 (7) :496-498.

[8]张孝国, 王敏, 陈建.丙型肝炎病毒RNA高变区准种复杂性与干扰素疗效关系的初步探讨[J].山东大学学报 (医学版) , 2008, 46 (2) :171-173.

[9]Hattori M, Yoshioka K, Aiyama T, et al.Broadly reactive antibod-ies to hepervariable region 1 in hepatitis C virus-infected patientssera:relation to viral loads and respond to interferon[J].Hepatolo-gy, 1998, 27 (6) :1703-1710.

[10]Liu L, Fisher BE, Dowd KA, et al.Acceleration of hepatitis C vi-rus envelope evolution in humans is consistent with progressive hu-moral immune selection during the transition from acute to chronicinfection[J].J Virol, 2010, 84 (10) :5067-5077.

[11]Fan X, Mao, Q, Zhou D, et al.High diversity of hepatitis C viralquasispecies is associated with early virological response in patientsundergoing antiviral therapy[J].Hepatology, 2009, 50 (6) :1765-1772.

施引文献

资源附件(0)

访问统计